The U.S. new cases 7-day rolling average are 16.5 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 1.3 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 54,520
U.S. Coronavirus deaths are at 950
U.S. Coronavirus immunizations have been administered to 69 doses per 100 people.
The 7-day rolling average rate of growth of the pandemic shows new cases were little changed and deaths worsened
How Molnupiravir Moved to the Head of the COVID Pill Pack
US cruises could restart soon with passenger voyages by mid-July, CDC says
Tags »
To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.
“To advance a drug quickly and across the globe in all the countries where it is needed, you need the capacity of a company like Merck,” said George Painter, PhD, CEO of the non-profit Emory-owned DRIVE (Drug Innovation Ventures at Emory), at a media briefing Tuesday. “It’s gratifying to see how quickly they moved and how they’re getting this into the hands of people in India to meet this threat.”
COVID-19: Oral drug treats SARS-CoV-2 infection in hamsters medicalnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalnewstoday.com Daily Mail and Mail on Sunday newspapers.
: Monday, April 19, 2021, 8:10 AM IST
FBL pioneers the development of its patented enzymatic route of synthesis for Molunpiravir an investigational âorally activeâ therapeutic alternative for COVID 19
This novel technology using green chemistry provides a sustainable, efficient and scalable form of treatment to fight against COVID 19
âWith the more we understand of COVID-19 the less we fear it and it is through this understanding that we can potentially create impressive therapeutic developments,â says Prashant Nagre, CEO, FBL as he expounds further on the experimental antiviral drug Molnupiravir. Developed at Emory University in Atlanta by Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Ridgeback Biotherapeutics, who later partnered with Merck & Co. to further develop the drug as they are encouraged by preliminary data from a Phase 2a trial of its COVID-19 oral antiviral treatment Molnupiravir. Molnupiravir originally developed for the tre
The News Scroll 19 April 2021
Last Updated at 12:32 pm | Source: PTI
Fermenta Biotech Limited develops enzymatic synthesis of Molnupiravir - an investigational COVID-19 therapeutic drug Outlook April 19, 2021 12:32 IST Fermenta Biotech Limited develops enzymatic synthesis of Molnupiravir - an investigational COVID-19 therapeutic drug outlookindia.com 1970-01-01T05:30:00+0530
(Eds: Disclaimer: The following content is a press release. PTI takes no editorial responsibility for the same.) Novel technology using green chemistry is sustainable, efficient and scalable
The experimental antiviral drug Molnupiravir was developed at Emory University in Atlanta by Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Ridgeback Biotherapeutics, who later partnered with Merck & Co. to further develop the drug. Molnupiravir, originally developed for the treatment of influenza, is orally active unlike other potential options of treat